Lung Cancer Clinical Trials in Houston

Showing 581-600 of 620 trials

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00416650

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with advanced non-small cell lung cancer.

Lung Cancer

Vanderbilt-Ingram Cancer Center16 participantsStarted Jul 2002

Chicago, Illinois, United States • New York, New York, United States • Nashville, Tennessee, United States +1 more locations

COMPLETED< 1 mile

Phase II Evaluation of Exhaled Nitric Oxide (NO)

NCT01392144

The goal of this clinical research study is to learn if the level of nitric oxide you breathe out may relate to the amount of breathing complications that you may experience due to radiation treatment.

Lung Cancer

M.D. Anderson Cancer Center36 participantsStarted Aug 2011

Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00777309

This is a randomized, placebo-controlled, double blind phase 2 study designed to compare treatment with ARQ 197 plus erlotinib to erlotinib plus placebo in patients with non-small cell lung cancer. The study will enroll patients who have had one prior chemotherapy regimen (other than erlotinib) for NSCLC.

Non Small Cell Lung Cancer

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)167 participantsStarted Sep 2008

Burbank, California, United States • Santa Monica, California, United States • Torrington, Connecticut, United States +35 more locations

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase II Evaluation of Exhaled Nitric Oxide (NO)

A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer Trials in Other Cities

S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

Multimedia Patient Education

Tracking of Respiratory-Induced Tumor Motion Using Implanted Fiducials

S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

Respiratory Tumor and Normal Tissue Motion

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

S9914: Combination Chemotherapy Plus Filgrastim in Untreated Extensive-Stage Small Cell Lung Cancer

S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer

S0229, Pulmonary Rehabilitation Education w/wo Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemo & RT for Locally Advanced Lung Cancer

S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Other Conditions in Houston